Home Companies Catalysts Deep Dives
Isentress raltegravir APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Launch2007-10-12
US LOE2024-01-01
Peak Sales Est$1800M
Formulations[{"id":"isentress-po","route":"PO","setting":"PATIENT_SELF","frequency":"BID/QD","is_primary":true}]
Companies
MRK (ORIGINATOR)100%
Mechanism: Integrase inhibitor
Expert: HIV integrase strand transfer inhibitor
Everyday: Blocks HIV from inserting its genetic material into cells
Targets: ["HIV INTEGRASE"]
Revenue History
PeriodRevenue ($M)
2023$892M
2024$542M
Programs (1)
IndicationStageKey StudyRegional Status
HIV-1 InfectionAPPROVEDBENCHMRK[{"stage":"APPROVED","region":"US","approval_date":"2007-10-12"}]
Notes
First integrase inhibitor. Now generic. Declining.
Data from Supabase · Updated 2026-03-24